This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (58)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Cardiovascular Disease/ Myocardial Infarction  • Cardiac Diagnostic Tests  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Elizabeth M. Mahoney, ScD; Claudine T. Jurkovitz, MD,MPH; Haitao Chu, MS; Edmund R. Becker, PhD; Steven Culler, PhD; Andrzej S. Kosinski, PhD; Debbie H. Robertson, RD,MS; Charles Alexander, MD; Soma Nag, MS; John R. Cook, PhD; Laura A. Demopoulos, MD; Peter M. DiBattiste, MD; Christopher P. Cannon, MD; William S. Weintraub, MD; for the TACTICS-TIMI 18 Investigators

JAMA. 2002;288:1851-1858.

Context  In the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS)–Thrombolysis in Myocardial Infarction (TIMI) 18 trial, patients with either unstable angina or non–ST-segment elevation myocardial infarction (UA/NSTEMI) treated with the platelet glycoprotein (Gp IIb/IIIa) inhibitor tirofiban had a significantly reduced rate of major cardiac events at 6 months with an early invasive vs a conservative strategy.

Objective  To examine total 6-month costs and long-term cost-effectiveness of an invasive vs a conservative strategy.

Design  Randomized controlled trial including a priori economic end points.

Setting  Hospitalization for UA/NSTEMI with 6-month follow-up period.

Patients  A total of 2220 patients with UA/NSTEMI; economic data from 1722 patients at US–non-VA hospitals.

Intervention  Early invasive strategy with routine catheterization and revascularization as appropriate vs a conservative strategy with catheterization performed only for recurrent ischemia or a positive stress test.

Main Outcome Measure  Total 6-month costs and incremental cost-effectiveness ratio.

Results  The average initial hospitalization costs among those in the invasive strategy group were $15714 vs $14047 among those in the conservative stategy group, a difference of $1667 (95% confidence interval [CI], $387-3091). The in-hospital costs were offset significantly at the 6-month follow-up, with an average cost in the invasive group of $6098 vs $7180 in the conservative group, a difference of $1082 (95% CI, -$2051 to $76). The average total costs at 6 months, including productivity costs, for the invasive group was $21 813 vs $21 227 for the conservative group, a $586 difference (95% CI, -$1087 to $2486). The average 6-month costs excluding productivity costs in the invasive group was $19 780 vs $19 111 in the conservative group, a difference of $670, 95% CI; (-$1035 to $2321). Estimated cost per year of life gained for the invasive strategy, based on projected life expectancy, was $12739 for the base case, and ranged from $8371 to $25769, based on model assumptions.

Conclusions  In patients with UA/NSTEMI treated with the Gp IIb/IIIa inhibitor tirofiban, the clinical benefit of an early invasive strategy was achieved with a small increase in cost, yielding favorable projected estimates of cost per year of life gained. These results support the broader use of an early invasive strategy in these patients.

Author Affiliations: Department of Medicine, Division of Cardiology, Emory University School of Medicine (Drs Mahoney, Jurkovitz, and Weintraub and Mr Chu) and Departments of Health Policy and Management, (Drs Becker and Culler), and Biostatics (Dr Kosinski), Emory University Rollins School of Public Health, Atlanta, Ga; Merck & Co, West Point, Pa (Mss Robertson and Nag and Drs Alexander, Cook, Demopoulos, and DiBattiste), Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass (Dr Cannon).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Invasive vs Conservative Management of Acute Coronary Syndromes: Do the Data Support the Guidelines?
David J. Cohen
JAMA. 2002;288(15):1905-1907.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Delays in angiography may cost lives
Rothman and De Palma
Heart 2009;95:1815-1817.
FULL TEXT  

Comorbid Depression and Anxiety Symptoms as Predictors of Cardiovascular Events: Results From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study
Rutledge et al.
Psychosom. Med. 2009;71:958-964.
ABSTRACT | FULL TEXT  

Depression and cardiovascular health care costs among women with suspected myocardial ischemia: prospective results from the WISE (Women's Ischemia Syndrome Evaluation) Study.
Rutledge et al.
J Am Coll Cardiol 2009;53:176-183.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients
Weintraub et al.
Circ Cardiovasc Qual Outcomes 2008;1:12-20.
ABSTRACT | FULL TEXT  

One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States
Mahoney et al.
Circ Cardiovasc Qual Outcomes 2008;1:38-45.
ABSTRACT | FULL TEXT  

Pharmacoeconomic Concepts in Antiplatelet Therapy: Understanding Cost-Effectiveness Analyses Using Clopidogrel as an Example
Weintraub
J CARDIOVASC PHARMACOL THER 2008;13:107-119.
ABSTRACT  

Evolution of the definition of myocardial infarction: what are the implications of a new universal definition?
White
Heart 2008;94:679-684.
FULL TEXT  

The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial
Henriksson et al.
Heart 2008;94:717-723.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post-Myocardial Infarction Medicare Beneficiaries
Choudhry et al.
Circulation 2008;117:1261-1268.
ABSTRACT | FULL TEXT  

Percutaneous coronary revascularisation: is it ever worth what it costs?
Mark
Heart 2007;93:1161-1163.
FULL TEXT  

Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Kaul
Eur Heart J 2007;0:ehm168v1-2.
FULL TEXT  

A Multinational Study to Establish the Value of Early Adenosine Technetium-99m Sestamibi Myocardial Perfusion Imaging in Identifying a Low-Risk Group for Early Hospital Discharge After Acute Myocardial Infarction
Mahmarian et al.
J Am Coll Cardiol 2006;48:2448-2457.
ABSTRACT | FULL TEXT  

The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease: Results From the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation
Shaw et al.
Circulation 2006;114:894-904.
ABSTRACT | FULL TEXT  

Additional Information
JAMA 2006;295:E1-E6.
FULL TEXT  

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone et al.
ANN INTERN MED 2006;144:326-336.
ABSTRACT | FULL TEXT  

The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis
Glaser et al.
J Am Coll Cardiol 2006;47:529-537.
ABSTRACT | FULL TEXT  

Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial
Beinart et al.
J Am Coll Cardiol 2005;46:761-769.
ABSTRACT | FULL TEXT  

Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation
Weintraub et al.
J Am Coll Cardiol 2005;45:838-845.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure
Weintraub et al.
Circulation 2005;111:1106-1113.
ABSTRACT | FULL TEXT  

Thrombocytopenia in Cardiovascular Patients: Diagnosis and Management
Matthai
Chest 2005;127:46S-52S.
ABSTRACT | FULL TEXT  

A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes
Gluckman et al.
JAMA 2005;293:349-357.
ABSTRACT | FULL TEXT  

Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: One-year results of the third randomized intervention trial of unstable angina (RITA-3)
Kim et al.
J Am Coll Cardiol 2005;45:221-228.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Dual-Chamber Pacing Compared With Ventricular Pacing for Sinus Node Dysfunction
Rinfret et al.
Circulation 2005;111:165-172.
ABSTRACT | FULL TEXT  

Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: Results from the SAFER trial
Cohen et al.
J Am Coll Cardiol 2004;44:1801-1808.
ABSTRACT | FULL TEXT  

The Effect of Routine, Early Invasive Management on Outcome for Elderly Patients with Non-ST-Segment Elevation Acute Coronary Syndromes
Bach et al.
ANN INTERN MED 2004;141:186-195.
ABSTRACT | FULL TEXT  

Economics of Sirolimus-Eluting Stents: Drug-Eluting Stents Have Really Arrived
Weintraub
Circulation 2004;110:472-474.
FULL TEXT  

Prognosis in Women With Myocardial Ischemia in the Absence of Obstructive Coronary Disease: Results From the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE)
Johnson et al.
Circulation 2004;109:2993-2999.
ABSTRACT | FULL TEXT  

Economic analysis of a transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation: The ACUTE economic data at eight weeks
Klein et al.
J Am Coll Cardiol 2004;43:1217-1224.
ABSTRACT | FULL TEXT  

Unstable Angina and Non-ST-Elevation Myocardial Infarction: Initial Antithrombotic Therapy and Early Invasive Strategy
Cannon and Turpie
Circulation 2003;107:2640-2645.
FULL TEXT  

JournalScan
Malik
Heart 2003;89:119-120.
FULL TEXT  

Invasive Strategy Cost-Effective for UA/NSTEMI Patients
Journal Watch Cardiology 2002;2002:7-7.
FULL TEXT  

Invasive vs Conservative Management of Acute Coronary Syndromes: Do the Data Support the Guidelines?
Cohen
JAMA 2002;288:1905-1907.
FULL TEXT